Recently, the discovery of fibroblast growth factor 21 (FGF21) as a novel anti-obesity and anti-inflammatory factor and as a downstream target of mutant KRAS has shed new light on this problem. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.